Read-Gene Overview

  • Founded
  • 2005

Founded
  • Status
  • Public

  • Employees
  • 23

Employees
  • Stock Symbol
  • RDG

Stock Symbol
  • Share Price
  • $0.45

  • (As of Tuesday Closing)

Read-Gene General Information

Description

Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Stock Exchange
WAR
Primary Office
  • Ul. Alabastrowa 8
  • Grzepnica, 72-003
  • Poland
+48 91 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Read-Gene Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.45 $0.47 $0.39 - $0.80 $5.58M 11.8M 2.1K

Read-Gene Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 4,569 6,487 6,641 1,013
Revenue 1,715 1,671 1,556 1,658
EBITDA 133 174 296 427
Net Income (10) 10 90 31
Total Assets 3,335 3,792 4,347 4,279
Total Debt 0 1,396 1,532 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Read-Gene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial